Catabasis Pharmaceuticls Inc. (CATB) Rating Reiterated by Wedbush

Catabasis Pharmaceuticls Inc. (NASDAQ:CATB)‘s stock had its “outperform” rating reissued by stock analysts at Wedbush in a note issued to investors on Thursday. They presently have a $17.00 price target on the stock. Wedbush’s price objective would suggest a potential upside of 249.08% from the company’s previous close.

Separately, Zacks Investment Research upgraded Catabasis Pharmaceuticls from a “hold” rating to a “buy” rating and set a $4.25 target price for the company in a research note on Tuesday, July 5th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Catabasis Pharmaceuticls currently has an average rating of “Buy” and a consensus price target of $19.05.

Catabasis Pharmaceuticls (NASDAQ:CATB) opened at 4.87 on Thursday. The company’s market capitalization is $74.91 million. Catabasis Pharmaceuticls has a 12-month low of $3.31 and a 12-month high of $10.83. The firm’s 50-day moving average price is $4.77 and its 200 day moving average price is $4.74.

Catabasis Pharmaceuticls (NASDAQ:CATB) last released its earnings results on Thursday, August 11th. The company reported ($0.61) earnings per share for the quarter, topping the consensus estimate of ($0.65) by $0.04. On average, analysts expect that Catabasis Pharmaceuticls will post ($2.47) earnings per share for the current year.

A hedge fund recently raised its stake in Catabasis Pharmaceuticls stock. Sphera Funds Management LTD. increased its stake in Catabasis Pharmaceuticls Inc. (NASDAQ:CATB) by 184.9% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 230,041 shares of the company’s stock after buying an additional 149,299 shares during the period. Sphera Funds Management LTD. owned approximately 1.50% of Catabasis Pharmaceuticls worth $1,159,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 57.27% of the company’s stock.

About Catabasis Pharmaceuticls

Catabasis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease.

5 Day Chart for NASDAQ:CATB

Receive News & Ratings for Catabasis Pharmaceuticls Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catabasis Pharmaceuticls Inc. and related companies with's FREE daily email newsletter.

Leave a Reply

© 2006-2016 Mideast Time.